Investments
13Portfolio Exits
12Partners & Customers
10Service Providers
2
Want to inform investors similar to Shire about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Shire News
Jan 9, 2023
Anglo-Irish company Amryt Pharma (LSE: AMYT) has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda (TYO: 4502) four years ago. Amryt may not have quite grown to Shire’s size, but its acquisition by privately-held Italian drugmaker Chiesi has vindicated the ambitious approach of its leadership team in turning it into one of the most exciting emerging companies in the rare diseases… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Shire Investments
13 Investments
Shire has made 13 investments. Their latest investment was in Rani Therapeutics as part of their Series D - II on February 2, 2018.
Shire Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/8/2018 | Series D - II | Rani Therapeutics | $53M | Yes | 8 | |
1/5/2017 | Series C | Translate Bio | $51M | Yes | Atlas Venture, Shire, and SR One | 3 |
9/7/2016 | Series E | Proclara Biosciences | $47M | No | 12 | |
1/14/2015 | Series D - II | |||||
3/25/2014 | Series D |
Date | 2/8/2018 | 1/5/2017 | 9/7/2016 | 1/14/2015 | 3/25/2014 |
|---|---|---|---|---|---|
Round | Series D - II | Series C | Series E | Series D - II | Series D |
Company | Rani Therapeutics | Translate Bio | Proclara Biosciences | ||
Amount | $53M | $51M | $47M | ||
New? | Yes | Yes | No | ||
Co-Investors | Atlas Venture, Shire, and SR One | ||||
Sources | 8 | 3 | 12 |
Shire Portfolio Exits
12 Portfolio Exits
Shire has 12 portfolio exits. Their latest portfolio exit was Rani Therapeutics on July 30, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/30/2021 | IPO | Public | 16 | ||
7/18/2019 | IPO | Mirum Pharmaceuticals | Public | 2 | |
11/7/2018 | Spinoff / Spinout | Mirum Pharmaceuticals | 1 | ||
Date | 7/30/2021 | 7/18/2019 | 11/7/2018 | ||
|---|---|---|---|---|---|
Exit | IPO | IPO | Spinoff / Spinout | ||
Companies | Mirum Pharmaceuticals | Mirum Pharmaceuticals | |||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 16 | 2 | 1 |
Shire Acquisitions
21 Acquisitions
Shire acquired 21 companies. Their latest acquisition was sanaplasma on September 07, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/7/2018 | Acquired | 1 | ||||
1/22/2016 | Other Venture Capital | $48.8M | Acq - P2P | 1 | ||
1/11/2016 | Acq - P2P | 2 | ||||
8/3/2015 | Other | |||||
2/24/2015 | Other Venture Capital |
Date | 9/7/2018 | 1/22/2016 | 1/11/2016 | 8/3/2015 | 2/24/2015 |
|---|---|---|---|---|---|
Investment Stage | Other Venture Capital | Other | Other Venture Capital | ||
Companies | |||||
Valuation | |||||
Total Funding | $48.8M | ||||
Note | Acquired | Acq - P2P | Acq - P2P | ||
Sources | 1 | 1 | 2 |
Shire Partners & Customers
10 Partners and customers
Shire has 10 strategic partners and customers. Shire recently partnered with Rio Tinto Group on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/25/2022 | Partner | United Kingdom | Rio Tinto and Ashburton Shire set up new screening clinic at Tom Price Hospital A partnership between the Shire and Rio Tinto has seen a new COVID-19 screening facility set up in Tom Price . | 1 | |
12/19/2018 | Partner | United States | `` Our partnership with SeriousFun has been a high-impact investment in the lives of children with rare diseases and other serious conditions and their families , '' said Linn Parrish , Shire 's Head of Corporate Responsibility . | 1 | |
12/17/2018 | Vendor | Germany | Laupheim , Germany and Milford , MA , USA , December 17 , 2018 -- Rentschler Biopharma , a leading contract development and manufacturing organization for biopharmaceuticals , announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston , MA , USA . | 1 | |
11/8/2018 | Licensee | ||||
11/5/2018 | Licensee |
Date | 2/25/2022 | 12/19/2018 | 12/17/2018 | 11/8/2018 | 11/5/2018 |
|---|---|---|---|---|---|
Type | Partner | Partner | Vendor | Licensee | Licensee |
Business Partner | |||||
Country | United Kingdom | United States | Germany | ||
News Snippet | Rio Tinto and Ashburton Shire set up new screening clinic at Tom Price Hospital A partnership between the Shire and Rio Tinto has seen a new COVID-19 screening facility set up in Tom Price . | `` Our partnership with SeriousFun has been a high-impact investment in the lives of children with rare diseases and other serious conditions and their families , '' said Linn Parrish , Shire 's Head of Corporate Responsibility . | Laupheim , Germany and Milford , MA , USA , December 17 , 2018 -- Rentschler Biopharma , a leading contract development and manufacturing organization for biopharmaceuticals , announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston , MA , USA . | ||
Sources | 1 | 1 | 1 |
Shire Service Providers
2 Service Providers
Shire has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor | |
Service Provider | ||
|---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.